Practical Considerations for Dose Selection in Pediatric Patients to Ensure Target Exposure Requirements
Journal Title: The AAPS Journal - Year 2014, Vol 16, Issue 4
Abstract
Pediatric dosing recommendations are often not based on allometry, despite recognition that metabolic processes in mammals scale to the ¾ power. This report reviews the allometric size model for clearance and its implications for defining doses for children while considering practical limitations. Fondaparinux exposures in children were predicted using allometric and mg/kg dosing. Additional simulations further refined the dose based on the predicted Cmax, target exposure range, complexity of the dosing regimen, and previous exposure/response data. The percent reduction of the adult dose of an oral lozenge fixed-dose formulation which would predict similar exposures in children and adults was recommended based on simulations. Allometric dosing predicted a consistent fondaparinux exposure across the weight range. Size-optimized mg/kg dosing, which partially approximates the allometric relationship, allows for consistent fondaparinux exposures (i.e., 0.12 mg/kg ≤35 kg or 0.1 mg/kg >35 kg). Simulations of the oral lozenge formulation demonstrated rapidly changing clearance in children less than 6 years prohibiting practical dosing recommendations for satisfying all conventional exposure metrics (Cmax and AUC) in this age group. In children between 13 and 18 or 6 and 13 years, a 8.6% and 54% reduction in dose would maintain target exposures but dose reductions of 12.5% or 62.5% were ultimately recommended as deemed manufacturable. Dose selection in children should consider the known and/or predicted covariate relationships which affect exposure. Presented examples applied the allometric model in dose selection with the goal of PK bridging and considered practical limitations in dose selection.
Authors and Affiliations
April M. Barbour, Michael J. Fossler, Jeffrey Barrett
Keywords
Related Articles
- EP ID EP681697
- DOI 10.1208/s12248-014-9603-x
- Views 97
- Downloads 0
Toward the prediction of CNS drug-effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic-pharmacodynamic modeling
Our ultimate goal is to develop mechanism-based pharmacokinetic (PK)-pharmacodynamic (PD) models to characterize and to predict CNS drug responses in both physiologic and pathologic conditions. To this end, it is essenti...
Duel-Acting Subcutaneous Microemulsion Formulation for Improved Migraine Treatment with Zolmitriptan and Diclofenac: Formulation and In Vitro-In Vivo Characterization
Subcutaneous triptan provides immediate analgesia in migraine and cluster headache but is limited by high pain recurrence due to rapid drug elimination. A dual-acting subcutaneous formulation providing immediate release...
Assessment of a Spectrophotometric Assay for Monoacylglycerol Lipase Activity
N-arachidonyl maleimide, methylarachidonyl fluorophosphonate, and arachidonoyl-1-thio-glycerol were purchased from Cayman Chemical Company (Ann Arbor, MI, USA). 5,5′-dithiobis(2-dinitrobenzoic acid) and 2-oleoylg...
Exposure-response relationships and drug interactions of sirolimus
Sirolimus (rapamycin, RAPAMUNE, RAPA) is an immunosuppressive agent used for the prophylaxis of renal allograft rejection and exhibits an immunosuppressive mechanism that is distinct from that for cyclosporine and tacrol...
PTD-mediated Loading of Tumor-Seeking Lymphocytes with Prodrug-Activating Enzymes
Using the approach of peptide transduction domain (PTD)-mediated loading of interleukin-2(IL-2)-activated natural killer (A-NK) cells, tumor-seeking lymphocytes, with prodrug-activating enzymes, we primarily aim to gener...